Novo Nordisk Fights Fake Wegovy/Ozempic and Faces Mounjaro’s Superior Study Results

Novo Nordisk has filed complaints against two Florida-based compounding pharmacies for marketing unapproved versions of its semaglutide products, claiming the products are weaker in strength than labeling indicates and may contain up to 33 percent impurities.
Source: Drug Industry Daily